La­va Ther­a­peu­tics makes cuts to its head­count

La­va Ther­a­peu­tics said Tues­day that it cut 36% of its staff af­ter the biotech stopped all work on a ther­a­py look­ing to go af­ter CD1d-ex­press­ing hema­to­log­i­cal tu­mors.

The com­pa­ny em­ployed 69 full-time em­ploy­ees as of Dec. 31, 2022. It told in­vestors this week that its cash run­way now ex­tends in­to 2026, and it’s pri­or­i­tiz­ing its work on LA­VA-1207, a metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer treat­ment in Phase I/IIa. La­va al­so ex­pects more da­ta on the drug with­in the next 12 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER